Abstract
Heart failure (HF) has an estimated prevalence of 1–2% in the world’s population and up to 10% of patients age 65 and above. Iron deficiency (ID) in HF has been shown to be an independent contributor of increased mortality and poorer quality of life and has been associated with increased rates of hospitalization. Estimates are varied, but it is believed that as many as 30–83% of HF patients have ID, often without overt anemia, therefore making diagnosis more difficult. Well-established large studies have shown intravenous iron (IVFe) supplementation in HF patients is superior to an oral route, though these guidelines were developed for the chronic HF patients in the outpatient setting. For patients who are frequently hospitalized for HF, their inpatient stays may present an opportunity to diagnose ID. We previously showed that ID is underdiagnosed in the inpatient setting. To date, limited studies investigate long-term outcomes in hospitalized HF patients diagnosed with ID who are treated with IVFe compared to those who are not. In this retrospective analysis, we assessed 1-year readmission rates and mortality outcomes in patients who were diagnosed with ID while admitted for HF and subsequently received IVFe versus those who did not on their initial admission. These data suggest that there is no significant reduction in readmissions for HF or mortality between those patients who received IVFe and those who did not.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Mosterd A, Hoes AW (2007) Clinical epidemiology of heart failure. Heart 93:1137–1146. https://doi.org/10.1136/hrt.2003.025270
Rocha BML, Cunha GJL, Menezes Falcão LF (2018) The burden of iron deficiency in heart failure. J Am Coll Cardiol 71:782–793. https://doi.org/10.1016/j.jacc.2017.12.027
Silverberg DS, Schwartz D, Schwartz I, Assa EB (2013) The missed opportunities to diagnose and treat iron deficiency in patients hospitalized with heart failure. Int J Cardiol 168:2164–2166. https://doi.org/10.1016/j.ijcard.2013.01.249
Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG, Tsagalou EP, Maroulidis GD, Alexopoulos GP, Kanakakis JE, Anastasiou-Nana MI (2006) Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 48:2485–2489. https://doi.org/10.1016/j.jacc.2006.08.034
Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, Lok DJ, Rosentryt P, Torrens A, Polonski L, van Veldhuisen DJ, van der Meer P, Jankowska EA (2013) Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 165:575–582.e3. https://doi.org/10.1016/j.ahj.2013.01.017
Cohen-Solal A, Damy T, Terbah M, Kerebel S, Baguet J-P, Hanon O, Zannad F, Laperche T, Leclercq C, Concas V, Duvillié L, Darné B, Anker S, Mebazaa A (2014) High prevalence of iron deficiency in patients with acute decompensated heart failure. Eur J Heart Fail 16:984–991. https://doi.org/10.1002/ejhf.139
Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJV, Anker SD, Ponikowski P (2010) Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 31:1872–1880. https://doi.org/10.1093/eurheartj/ehq158
Jankowska EA, Tkaczyszyn M, Suchocki T, Drozd M, von Haehling S, Doehner W, Banasiak W, Filippatos G, Anker SD, Ponikowski P (2016) Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials: Intravenous iron therapy in systolic heart failure. Eur J Heart Fail 18:786–795. https://doi.org/10.1002/ejhf.473
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C (2017) 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America. Circulation 136. https://doi.org/10.1161/CIR.0000000000000509
Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan B-A, Mori C, von Eisenhart RB, Pocock SJ, Poole-Wilson PA, Ponikowski P (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361:2436–2448. https://doi.org/10.1056/NEJMoa0908355
Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD, for the CONFIRM-HF Investigators (2015) Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 36:657–668. https://doi.org/10.1093/eurheartj/ehu385
Mistry R, Hosoya H, Kohut A, Ford P (2019) Iron deficiency in heart failure, an underdiagnosed and undertreated condition during hospitalization. Ann Hematol 98:2293–2297. https://doi.org/10.1007/s00277-019-03777-w
Zdravkovic SC, Nagorni SP, Cojbasic I, Mitic V, Cvetkovic P, Nagorni I, Govedarovic N, Davinic I, Stanojevic D (2019) Effects of 6-months of oral ferrous and ferric supplement therapy in patients who were hospitalized for decompensated chronic heart failure. J Int Med Res 47:3179–3189. https://doi.org/10.1177/0300060519847352
Niedziela JT, Parma Z, Pawlowski T, Rozentryt P, Gasior M, Wojakowski W (2018) Secular trends in first-time hospitalization for heart failure with following one-year readmission and mortality rates in the 3.8 million adult population of Silesia, Poland between 2010 and 2016. The SILCARD database. Int J Cardiol 271:146–151. https://doi.org/10.1016/j.ijcard.2018.05.015
Krumholz HM, Hsieh A, Dreyer RP, Welsh J, Desai NR, Dharmarajan K (2016) Trajectories of risk for specific readmission diagnoses after hospitalization for heart failure, acute myocardial infarction, or pneumonia. PLOS ONE 11:e0160492. https://doi.org/10.1371/journal.pone.0160492
Yeung DF, Boom NK, Guo H, Lee DS, Schultz SE, Tu JV (2012) Trends in the incidence and outcomes of heart failure in Ontario, Canada: 1997 to 2007. Can Med Assoc J 184:E765–E773. https://doi.org/10.1503/cmaj.111958
Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, Ferrari R, Piepoli MF, Jimenez JFD, Metra M, Fonseca C, Hradec J, Amir O, Logeart D, Dahlström U, Merkely B, Drozdz J, Goncalvesova E, Hassanein M, Chioncel O, Lainscak M, Seferovic PM, Tousoulis D, Kavoliuniene A, Fruhwald F, Fazlibegovic E, Temizhan A, Gatzov P, Erglis A, Laroche C, Mebazaa A (2016) European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail 18:613–625. https://doi.org/10.1002/ejhf.566
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the University of Pennsylvania (confirmation number: cijfeghj; IRB protocol number: 829971) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Mistry, R.H., Kohut, A. & Ford, P. Correction of iron deficiency in hospitalized heart failure patients does not improve patient outcomes. Ann Hematol 100, 661–666 (2021). https://doi.org/10.1007/s00277-020-04338-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-020-04338-2